bluebird bio, Inc. (NASDAQ:BLUE) insider Jeffrey T. Walsh sold 4,900 shares of the business’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $125.73, for a total value of $616,077.00. Following the transaction, the insider now directly owns 32,205 shares of the company’s stock, valued at approximately $4,049,134.65. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

bluebird bio, Inc. (BLUE) opened at 131.85 on Friday. The firm’s market cap is $6.01 billion. The firm has a 50-day moving average price of $105.28 and a 200 day moving average price of $96.03. bluebird bio, Inc. has a 12-month low of $37.05 and a 12-month high of $136.85.

bluebird bio (NASDAQ:BLUE) last released its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.66) by ($0.07). bluebird bio had a negative net margin of 1,080.59% and a negative return on equity of 32.19%. The business had revenue of $16.70 million during the quarter, compared to analyst estimates of $6.29 million. During the same quarter in the previous year, the firm posted ($1.59) earnings per share. The firm’s quarterly revenue was up 977.4% on a year-over-year basis. Equities research analysts forecast that bluebird bio, Inc. will post ($6.84) EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/09/15/jeffrey-t-walsh-sells-4900-shares-of-bluebird-bio-inc-blue-stock.html.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. FMR LLC raised its position in shares of bluebird bio by 9.6% in the second quarter. FMR LLC now owns 6,713,949 shares of the biotechnology company’s stock valued at $705,301,000 after buying an additional 587,236 shares in the last quarter. Capital Research Global Investors raised its position in shares of bluebird bio by 9.9% in the second quarter. Capital Research Global Investors now owns 5,483,117 shares of the biotechnology company’s stock valued at $576,001,000 after buying an additional 493,072 shares in the last quarter. Baillie Gifford & Co. raised its position in shares of bluebird bio by 3.8% in the second quarter. Baillie Gifford & Co. now owns 5,400,658 shares of the biotechnology company’s stock valued at $567,339,000 after buying an additional 196,025 shares in the last quarter. Vanguard Group Inc. raised its position in shares of bluebird bio by 10.7% in the second quarter. Vanguard Group Inc. now owns 3,559,102 shares of the biotechnology company’s stock valued at $373,884,000 after buying an additional 343,856 shares in the last quarter. Finally, BlackRock Inc. raised its position in shares of bluebird bio by 4.3% in the second quarter. BlackRock Inc. now owns 3,320,329 shares of the biotechnology company’s stock valued at $348,801,000 after buying an additional 138,141 shares in the last quarter.

Several equities analysts recently weighed in on the company. Barclays PLC assumed coverage on bluebird bio in a research report on Wednesday, September 6th. They set an “overweight” rating and a $151.00 price objective for the company. Wells Fargo & Company reissued an “outperform” rating and set a $158.00 price objective (up previously from $134.00) on shares of bluebird bio in a research report on Tuesday, September 5th. Wedbush reissued an “outperform” rating and set a $135.00 price objective (up previously from $121.00) on shares of bluebird bio in a research report on Friday, September 1st. Cowen and Company reissued an “outperform” rating on shares of bluebird bio in a research report on Thursday, August 31st. Finally, Evercore ISI assumed coverage on bluebird bio in a research report on Wednesday, August 16th. They set an “in-line” rating and a $102.00 price objective for the company. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and thirteen have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $107.86.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Insider Buying and Selling by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.